Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
$17.95
-$0.64(-3.70%)
At close: 4:00 PM EST
$17.95
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$14.14 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)83.89K
Market Cap
$225.77M
Enterprise Value$136.31M
Total Cash (Recent Filing)$59.09M
Total Debt (Recent Filing)$9.33M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 12, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding12,835,186
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.69
Price to Sales (P/S)8.77
P/FCF Ratio-8.91
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue6.51
Enterprise Value/Gross Profit35.14
Enterprise Value/Ebitda-12.47
Forecast
1Y Price Target
$31.50Price Target Upside75.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquidityStrong cash position, no debt, and recent capital raises improve liquidity to fund the manufacturing ramp and late-stage clinical programs without immediate financing pressure.
Clinical And Regulatory PathwayLate-stage venous leg ulcer study and a planned head-to-head trial versus the market leader aim to support regulatory approval and strengthen pricing and reimbursement discussions for EscharEx.
Manufacturing CapacityCompleted manufacturing buildout with a sixfold capacity increase is on track to begin commercial production in mid-2026, positioning the company to meet excess demand and support revenue growth.
Bears Say
Business And Execution RisksInvestment case remains exposed to clinical, regulatory, commercial, collaboration, and intellectual property risks that could delay approvals, uptake, or valuation realization.
Financial PerformanceReported operating and net losses highlight ongoing cash burn and the potential need for additional capital to sustain commercial expansion and development plans.
Government Contract TimingGovernment shutdown disrupted BARDA stockpiling negotiations, reducing revenue visibility and creating uncertainty around the timing of government payments.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.14 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $225.77M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Mar 12, 2026 which is in 27 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Nov 20, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.812 by $0.572.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.65.
How many shares outstanding does Mediwound have?
Mediwound has 12,835,186 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.812. Following the earnings report the stock price went down -5.599%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (75.49% Upside)
$31.50 (75.49% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.91%
12-Months-Change
Fundamentals
Return on Equity
-48.83%
Trailing 12-Months
Asset Growth
26.35%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials and manufacturing capabilities, as well as strong revenue growth. However, these were offset by increased operating losses and uncertainties related to government contracts and clinical trial timelines.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$31.50
▲(75.49% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
Ventyx Biosciences
―
Tevogen Bio Holdings
―
Ownership Overview
―
Insiders
4.95% Mutual Funds
1.77% Other Institutional Investors
89.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---